Investigating the Antidiabetic Effect of Metformin on Pyruvate Carboxylase by Solis, Guadalupe A.
Ursidae: The Undergraduate Research Journal at the University
of Northern Colorado
Volume 7
Number 2 McNair Special Issue Article 2
May 2019
Investigating the Antidiabetic Effect of Metformin
on Pyruvate Carboxylase
Guadalupe A. Solis
University of Northern Colorado, soli0731@bears.unco.edu
Follow this and additional works at: https://digscholarship.unco.edu/urj
Part of the Biology Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by Scholarship & Creative Works @ Digital UNC. It has been accepted for inclusion in Ursidae:
The Undergraduate Research Journal at the University of Northern Colorado by an authorized editor of Scholarship & Creative Works @ Digital UNC.
For more information, please contact Jane.Monson@unco.edu.
Recommended Citation
Solis, Guadalupe A. (2019) "Investigating the Antidiabetic Effect of Metformin on Pyruvate Carboxylase," Ursidae: The Undergraduate
Research Journal at the University of Northern Colorado: Vol. 7 : No. 2 , Article 2.
Available at: https://digscholarship.unco.edu/urj/vol7/iss2/2
 Investigating the Antidiabetic Effect of Metformin on Pyruvate Carboxylase 
Guadalupe Andrea Solis 
Mentors: Corina E. Brown, Ph.D., & Richard M. Hyslop, Ph.D., Chemistry and Biochemistry 
 
Abstract: Metformin is the most commonly prescribed treatment for type II diabetes. While the clinical effects of 
this generic drug are established, exact targets of metformin action remain unclear. The hypothesis of the present 
study was that metformin lowers blood glucose through inhibition of pyruvate carboxylase (PC), an enzyme 
catalyzing the first committed step of gluconeogenesis. Because metformin is relatively low cost, it is widely 
accessible to communities worldwide; currently, 150 million individuals depend on metformin for treatment. 
Thorough investigation of all targets involved in action of metformin becomes crucial, as it further explains the 
adverse effects of the drug. The specific activity of purified bovine PC was measured spectrophotometrically 
through the loss of absorbance at 340nm, following the oxidation of NADH. The design involved a series of 
enzyme-coupled assays treated with or without metformin (250-2,500 μM). Waller-Duncan post-hoc analysis 
revealed significant inhibition between controlled and treated groups at 500-2,500μM of metformin for the assays. 
Supporting results provide further insight into mechanisms of action behind metformin, as well as provide further 
explanation for the effects users experience. 
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Type II diabetes affects communities 
worldwide. As of 2014, 29.1 million people were 
diagnosed with diabetes in the United States alone 
(Centers for Disease Control and Prevention, 
2014a). Metformin lowers blood glucose levels 
and promotes insulin sensitivity of target organs. 
While gluconeogenesis has been established as 
the key pathway through which metformin 
mediates its physiological effects (Gastaldelli et 
al., 2000; Magnusson, Rothman, Katz, & 
Shulman, 1992; Rossetti et al., 1993), the exact 
targets of the drug are currently unknown, 
although there have been several proposed 
candidates (e.g., Cao et al., 2014; Foretz et al., 
2010; Madiraju et al., 2014; Shaw et al., 2005; 
Zhou et al., 2001). Past data suggests metformin 
might induce its anti-diabetic effects through the 
inhibition of pyruvate carboxylase (PC), a primary 
enzyme involved in the first committed step of 
gluconeogenesis. Thus, the hypothesis of this 
study is that metformin inhibits gluconeogenesis 
through the inhibition of pyruvate carboxylase at 
concentrations near pharmacokinetic range. 
Analysis of the effects of metformin on PC will 
help determine if the drug directly targets PC 
enzymatic activity. Support of this hypothesis will 
suggest a new target involved in the anti-
gluconeogenic action of metformin. Currently, the  
 
most current [drug] therapies available for 
treatment of type II diabetes fall under 11 
chemical groups  that include the guanidines 
(Close et al., 2012). Derived from the plant 
Galega officinalis, uses for guanidines in treating 
diabetes were documented as early as the 17th 
century, when physicians first began to describe 
and characterize type II diabetes (Bailey & Day, 
2004). It was not until 1918 that Watanabe first 
published data demonstrating the guanidine plant 
extract possessed hypoglycemic activity. In 1994 
the Federal Drug Administration in the United 
States approved dimethylbiguanide hydrochloride 
(Figure 1), or Metformin; itis currently the most 
commonly prescribed drug for type II diabetes 
treatment (Bailey & Day, 2004; He & 
Wondisford, 2015). Given clinically in Europe 
since the 1920’s (Kaneto et al., 2016), Metformin 
is prescribed for treatment of hyperglycemia, a 
primary characteristic of type II diabetes (Irons & 
Minze, 2014). 
Figure 1. Carbon structure of Metformin, or 
dimethylbiguandine. Adapted from “Glyburide 
Microionized and  Metformin Hydrochloride,” by 
E.M. Lamos, S.A. Stein, and S.N. Davis, 2012, Expert 
Opinion on Pharmacotherapy. 
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Purpose and Significance 
Given the many contradictory findings, this 
study aimed to compare the effects of metformin 
on PC. Specific ranges of concentrations (250-
2,500μM) were used to assess past observations 
that proposed other mechanisms behind 
metformin action (Cao et al., 2014; Madiraju et 
al., 2014; Foretz et al., 2010; Zhou et al., 2001). 
Support of this hypothesis will aid in supporting 
PC as one of the key targets involved in the route 
of action for metformin. Observed inhibition will 
also support the metabolic control theory, stating 
a major metabolic pathway such as 
gluconeogenesis cannot solely be controlled by 
one primary enzyme (Fell, 1997). 
Adverse Effects of Metformin 
The importance of perusing metformin is also 
highlighted by the documented adverse effects of 
the drug. Gastrointestinal imbalances such as 
increased flatulence, diarrhea, abdominal pain, 
and decreased absorption of vitamin B12 have 
been reported (He et al., 2009). Metformin users 
with predisposing conditions, such as liver or 
kidney disease, fall risk for developing lactic 
acidosis: a toxic and potentially deadly condition 
with severe symptoms such as vomiting, diarrhea 
and renal impairment (Duong et al., 2013). It is of 
benefit to fully understand metformin, as the drug 
is widely used around the world for a disease that 
is quickly becoming a pandemic. 
Type II Diabetes Prevalence in 
Underrepresented Populations 
With the incidence of type II diabetes growing 
at astonishing rates, 2 out of 5 people in the U.S. 
are expected to develop type II diabetes in their 
lifetimes (Centers for Disease Control and 
Prevention, 2014a). More than half of non-
Hispanic black women and Hispanic men and 
women are predicted to develop the disease within 
their lifetime (Centers for Disease Control and 
Prevention, 2014b).  The observations from this 
study helped provide greater insight into the 
specific targets involved in diabetic treatment that 
help aid in the development of more effective 
methods for treatment that will provide efficient 
care to these growing and underrepresented 
populations. 
LITERATURE REVIEW 
Type II Diabetes 
The disease state of type II diabetes is 
characterized by an increase in fasting glucose 
production and increased insulin resistance. The 
physiological effects of type II diabetes are 
mediated via many metabolic pathways including 
gluconeogenesis, which produces glucose from 
non-carbohydrate sources when stressed or 
starving (Burgess et al., 2007; Cox & Nelson, 
2013). The sources for gluconeogenesis, lactate 
and pyruvate, are derived from the breakdown of 
fat and protein stores that the body utilizes 
throughout these periods (Hanson & Owen, 
2013). In the case of type II diabetes, 
gluconeogenesis is inappropriately upregulated in 
the liver, triggered by abnormal drops in insulin 
levels (Hanson & Owen, 2013). Insulin is secreted 
by pancreatic β islet cells, which critically 
function to control and stabilize blood glucose 
levels (Guerra et al., 2005). During high 
carbohydrate states in a non-diabetic patient, the 
body responds through immediate secretion of 
insulin and innate suppression of 
gluconeogenesis. However, cells become resistant 
to the effects of insulin in type II diabetes, leading 
to decreased glucose stability and persistent 
hyperglycemic conditions even during fasting 
states (Hanes & Krishna, 2010). Regulation of 
hepatic gluconeogenesis during hyperglycemic 
states has therefore been identified as a key 
element involved in the route of action for 
metformin (An & He, 2016).  
Phosphoenolpyruvate Carboxykinase.  
Hepatic gluconeogenesis involves two main 
enzymes, PC in the mitochondria and 
phosphoenolpyruvate carboxykinase (PEPCK) in 
the cytosol. PEPCK catalyzes the last committed 
step of gluconeogenesis and is responsible for the 
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 production of phosphoenolpyruvate from 
oxaloacetate, see Figure 2; (Hanson et al., 2013; 
Hanson & Garber, 1972). Rognstad (1979) 
established PEPCK as dominant over control of 
gluconeogenesis due to its rate limiting action 
over the pathway. Expression of PEPCK increases 
2.9-fold in mouse adipose and liver tissue during 
many forms of chemically induced diabetes 
(Veneziale, Donofrio, & Nishimura, 1983) 
suggesting a role in diabetic pathogenesis and 
maintenance. PEPCK’s dominant role in the 
reaction has even allowed it to be used in 
molecular and pharmaceutical studies as a reliable 
indicator of gluconeogenic activity (Chakravarty 
et al., 2005). Yet other studies have argued against 
the close relation of PEPCK and control of 
gluconeogenesis during type II diabetes. In high-
fat-fed diabetic hyperglycemic mice, no 
significant correlation between PEPCK mRNA 
expression and high plasma glucose 
concentrations were found (Samuel et al., 2009). 
In vitro protein analysis of isolated murine hepatic 
cells suggested a weak correlation between 
PEPCK protein levels and diabetic 
hyperglycemia. The study generated a metabolic 
control coefficient of 0.18 for PEPCK, suggesting 
weak control over gluconeogenesis (Burgess et 
al., 2007). The aforementioned data challenges the 
notion that PEPCK is dominant in the control of 
gluconeogenesis, leaving room for other possible 
candidates of control.  
Pyruvate Carboxylase 
PC is an anapleurotic enzyme that catalyzes 
the first committed step of gluconeogenesis 
(Jitrapakdee et al., 2008) and converts pyruvate 
into oxaloacetate (see Figure 2). There is renewed 
interest in PC as data suggests greater 
involvement for control of gluconeogenesis 
during type II diabetes.  
During the disease state, insulin released from 
pancreatic β-islet cells becomes desensitized, 
leading to increased insulin resistance in patients 
even during hyper states of insulin secretion 
(Guerra et al., 2005). Proper receptor signaling for 
glucose uptake by target organs fails, leading to 
constant hyperglycemic conditions in circulation 
(Liang et al., 2011). Researchers have found high 
levels of PC expression in pancreatic β islet cells, 
though no significant expression of PEPCK was 
observed (Bonner-Weir & Weir, 2004; Sugden et 
al., 2011). High fat diet mice also showed lower 
productions of malate, a gluconeogenic output, 
when treated with metformin (Lee et al., 2013). 
Reduction of malate following metformin 
treatment could suggest possible upstream 
inhibition of PC activity. PC loss of function in 
adipose and liver tissue leads to reduced fasting 
hyperglycemia, fasting plasma insulin 
concentrations, and endogenous glucose 
production in high-fat-fed rats (Kumashiro et al., 
2013), its loss directly mimicking the antidiabetic 
effects of metformin. Overall, these studies 
suggest that PC may play a key role in the route 
by which metformin decreases hepatic 
gluconeogenesis and improves insulin secretion in 
type II diabetes, suggesting an unknown purpose 
for PC in these cells.  
Pharmacokinetics of Metformin 
The maximum clinical dosage for metformin 
in humans is 35 mg /kg body weight (Ismail, 
Soliman, & Nassan, 2015). Following oral 
administration, metformin is absorbed into the 
gastrointestinal tract where it enters the liver via 
the hepatic portal vein (Figure 3). In the portal 
vein, plasma metformin concentrations are 
reported to be between 40-70 μM (Duong et al., 
2013). Upon entry into the liver, metformin 
concentrations in primary hepatocytes rise to 220 
μM (Jin et al., 2009). Following uptake from the 
liver, metformin is distributed into the rest of the 
body, where concentrations reportedly drop near a 
range of 10-40 μM (He & Wondisford, 2015).  
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 Figure 2. The pathway for mitochondrial gluconeogenesis is enzyme coupled in nature. Pyruvate carboxylase 
catalyzes the first step and Malate Dehydrogenase the second. From “Gluconeogenesis for medical school,” by 
R.,Kiran.http://www.slideshare.net /ravikiran35977897/gluconeogenesis-for-medical-school. 
 
 
Figure 3. The pharmacokinetic route of metformin is 
illustrated. Once ingested, metformin is transported to 
the liver via the hepatic portal vein. Metformin 
proceeds to enter the general circulation system for 
renal absorption and elimination. 
 
The Adenosine Monophosphate-Activated 
Protein Kinase Pathway 
Adenosine monophosphate activated protein 
kinase (AMPK) is an enzyme catalyzed pathway 
regulating cellular response, metabolism, growth 
and organelle function (Zaha & Young, 2012). 
The downstream LKB1 protein kinase is 
significant in the activation of the AMPK pathway 
during times of energetic stress (Foretz et al., 
2005). Studies have claimed inhibition of 
gluconeogenesis by metformin actually results 
from the phosphorylation of the AMPK pathway 
(Cao et al., 2014; Shaw et al., 2005; Zhou et al., 
2001). Non-obese mice without sufficient levels 
of hepatic LKB1 kinase demonstrated an impaired 
ability to reduce blood glucose levels following an 
intraperitoneal glucose injection (Shaw et al., 
2005). In the same study, non-obese LKB1-
deficient mice treated with metformin also failed 
to reduce blood glucose levels, while non-obese, 
wild-type mice demonstrate reduced levels by 
more than 50%. The LKB1 deficient mice were 
not obese when undergoing this study, a physical 
characteristic found in approximately 84.7% of 
adults, 18 or over, with the disease (Centers for 
Disease Control and Prevention, 2010).  
METHOD 
The hypothesis that metformin interacts in an 
inhibitory manner with PC action was assessed 
via kinetic analysis of the rate of the enzyme-
coupled reaction of interest. Studies were 
performed through the Department of Chemistry 
and Biochemistry at the University of Northern 
Colorado, Greeley. 
Malate Dehydrogenase (MDH) Assay 
To assure that metformin did not affect MDH 
activity, spectrophotometric assays (Figure 4) for 
MDH were run using metformin concentrations of 
500μM, 1000μM and 5,000μM. All 
concentrations were prepared in ultra-pure water 
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 accordingly. Reaction media for all assays with 
and without metformin were mixed in a final 1mL 
cuvette volume with 0.20 mM NADH, 10 mM 
oxaloacetate, and MDH with 50 mM Tris-HCl 
buffer, pH 7.8, 30 ºC (Worthington Biochemical 
Corporation). Assays had a total run time of 1 min 
and a cycle time of 5 s. 
Figure 4. Reaction for MDH, part two of 
mitochondrial gluconeogenesis, is shown. 
Oxaloacetate is converted into malate via MDH using 
NADH as a coenzyme in the reaction. Loss of 
absorbance at 340 nm was used to determine the rate 
of the reaction. 
 
Pyruvate Carboxylase Assay  
The protocol for the enzyme coupled reaction 
(Figure 5) was adapted from various sources 
(Bahl et al., 1997; Duggelby et al., 1982; 
Jitrapakdee et al., 2008; Warren & Tipton, 1974). 
Optimal assay temperature for the reaction was 
maintained at 30ºC with a total run time of 1 min 
and a cycle time of 5 s. Reaction media for all 
assays with and without metformin were mixed in 
a 1mL cuvette volume with Triethanolamine 
buffer, Magnesium Sulfate, Pyruvic acid and 
Bovine Serum Albumin (BSA) in buffer solution. 
MDH in excess was prepared in Aceytl-
Coenzyme A solution and ATP were added to 
Triethanolamine (TEA) solution. PC enzyme 
solution contained Glycerol, Magnesium Acetate, 
and EDTA Tris-HCl buffer, adjusted to pH 7.8 
using 1M HCl or 1M KOH as necessary, differing 
metformin solutions were prepared in ultra-pure 
water accordingly. For control trials, all 
conditions were kept constant and metformin 
volume was replaced by TEA (background) buffer 
during control trials.  
Figure 5. The reaction for mitochondrial 
gluconeogenesis (above) were run for 
spectrophotometric analysis. 
 
Determination of Enzymatic Activity 
A diode array spectrophotometer, provided by 
the University of Northern Colorado Department 
of Chemistry and Biochemistry, was utilized for 
kinetic measurements on the enzymatic reactions 
of interest (Figure 4 and 5). Using Beer’s law, 
rates of the enzymatic reactions were converted 
into a rate, or loss of absorbance at 340 nm, in 
moles/sec. All runs were initiated with a blank test 
at an absorbance equal to 0 AU. The diode array 
spectrophotometer was allowed sufficient time 
(>30 min) for temperature equilibration prior to 
use. 
Statistical Analysis 
Enzyme activity (rate = ∆absorbance340nm/
sec) of experimental and control groups were 
compared analyzed via one-way analysis of 
variance (ANOVA) and significantly different 
groups were followed up by Waller-Duncan post-
hoc analysis using SAS version 9.4 software 
(Cary, NC). What was your level of significance 
that you were looking for? 
RESULTS 
MDH and Metformin 
Being that mitochondrial gluconeogenesis is 
enzyme-coupled in nature, it was necessary to 
assess potential inhibitory effects of metformin on 
MDH. One-way ANOVA revealed no significant 
difference between treated and controlled groups 
F(3, 8) = 1.150, p = 0.38 (Figure 7, Table 1).  
PC and Metformin 
One-way ANOVA revealed a significant 
difference between treated and controlled groups, 
F(4, 10) = 5.06, p = .0172. The Waller-Duncan 
post-hoc analysis confirmed a significant 
difference between control and treated groups at 
500μM, 1,000μM and 2,500μM (M = 1.98E -7). 
However, no significant difference for 
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 concentration group 250μM was observed 
compared to control (see Figure 8, Table 2).  
Figure 6. The loss of absorbance at 340 nm is illustrated above. For every reaction run, the diode array provides 
similar outputs. The diagram serves to confirm the reaction has begun catalysis upon addition of ATP  
 
Figure 7. Graphical representation of the average rates (mol/sec) of MDH reactions treated with 500μM-5,000μM 
of metformin plus the controls are shown above. Rates have a downward slope signifying a loss of absorbance of 
NADH at 340nm. No significant differences were found between treated and controlled groups.  
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 Figure 8. Graphical representation of the average rates (mol/sec) of the enzyme-coupled reactions treated with 
250μM-2,500μM of metformin plus the controls are shown above. Significant differences between 500μM, 
1,000μM and 2,500μM were found. 
 
 
Table 1. Numerical data for average rates of MDH 
reactions run are provided above. Rates were not 
found to be statistically significant from control. 
Table 2. Averages for the enzyme-coupled 
reaction are enumerated above. Significant 
differences* were found between 500-2,500μM 
and control. 
 
 
 
 
 
 
 
 
 
Concentration Avg. Rate (Mol/sec) 
500 2.04 E-6 
1,000 1.75 E-7 
5,000 
Control 
2.83 E-7 
3.05 E-7 
Concentration Avg. Rate (Mol/sec) 
250 2.89 E-7 
500 1.98 E-7* 
1,000 
2,500 
Control 
1.12 E-7* 
1.28 E-7* 
4.34 E-7* 
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Figure 9. Average NADH conversion to NAD+ per concentration of metformin. 
 
  
DISCUSSION 
In this study, PC activity was not significantly 
inhibited for concentrations below 250μM. 
Duncan-Waller post-hoc analysis found that 
metformin treatment significantly inhibited 
pyruvate carboxylase activity at concentrations 
500μM ≥ compared to control. As the 
concentration of metformin increased, the average 
rate of the reaction (Figure 8; Table 2). These 
results are consistent with those of other reported 
studies, as shown by Foretz et al (2010) and Cao 
et al (2014) where only concentrations above 
500μM were found to significantly inhibit 
gluconeogenesis as a whole. On the contrary, this 
study focused solely on PC activity and not 
gluconeogenesis as a whole. Figure 9 illustrates 
the difference in conversion of NADH → NAD+ 
between treated and controlled groups, where less 
conversion occurred as metformin concentrations 
increased, also supporting the observed results 
from this study. 
Results from this study add to the present 
debate regarding metformin activity. Although 
concentrations above 1,000μM are not 
pharmacokinetically relevant to those reported in 
animals and humans (Duong et al., 2013; He and 
Wondisford, 2015; Jin et al., 2009), 
concentrations having a statistically significant 
inhibition on pyruvate carboxylase activity in this 
study were closer to physiological range than past 
studies, where metformin action was claimed to 
be mediated through the AMPK pathway using 
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 suprapharmacological concentrations around 
10,000μM (He et al., 2009).  
Limitations 
Due to small group sizes and the relative 
novelty of this study, difficulty arose when 
attempting to closely simulate potential 
encounters occurring in-vivo. A higher number of 
repetition will be needed to strengthen the study 
in the future.  
Future Studies 
Results from this study are primary, as future 
research is needed to focus on examining the 
activity of PC at very specific concentration 
ranging between 70-250μM at high replication in 
order to observe exact thresholds at which 
metformin no longer inhibits PC activity. 
Assessment of this data may allow us to further 
judge the validity of these results, allowing us to 
uphold more concrete conclusions in the future. 
Future studies could also focus on assessing the 
potential interaction between metformin and other 
key gluconeogenic factors such as biotin, a 
prosthetic group of PC. 13C-NMR analysis may 
be used to assess the potential binding interaction 
through disappearance of key carbon groups of 
biotin, specifically the carbonyl side chain used to 
bind to PC. 
Implications 
This study provides further observation that 
may help direct future studies regarding the 
mechanism of action for this drug and better 
understanding the mechanism. The importance of 
understanding the metformin route of action 
during type II diabetes is crucial. Metformin has 
become a drug of choice for these patients due to 
its low cost and relatively safe profile. Aside from 
being used to treat type II diabetes, metformin is 
also prescribed for weight loss in obese 
individuals (Inzucchi et al., 2012) and as a 
complimentary drug for PCOS patients to induce 
ovulation. The drug has recently been shown to 
contain anti-cancer properties by increasing 
survival rates in patients with breast cancer 
(University of Pennsylvania School of Medicine, 
2016). Metformin continues to be the most 
popular around the world among other glucose 
lowering agents such as thiazolidinediones, 
sulfonylureas and others. Being that metformin is 
in high demand, it is important to keep 
characterizing the symptoms, side effects and 
benefits along with the mechanism behind them. 
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